Molecular Formula | C18H18N4O3S |
Molar Mass | 370.43 |
Density | 1.360±0.06 g/cm3(Predicted) |
Boling Point | 604.1±65.0 °C(Predicted) |
Solubility | DMSO: ≥ 47 mg/mL |
pKa | 10.27±0.60(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
In vitro study | LDC000067 reduces mESCs by Ser2-P, induces p53 activation, and leads to apoptosis. In addition, LDC067 also dose-dependently inhibited the de novo RNA synthesis of P-TEFb-dependent cellular genes. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.7 ml | 13.498 ml | 26.996 ml |
5 mM | 0.54 ml | 2.7 ml | 5.399 ml |
10 mM | 0.27 ml | 1.35 ml | 2.7 ml |
5 mM | 0.054 ml | 0.27 ml | 0.54 ml |
biological activity | LDC000067 (LDC067) is a highly selective CDK9 inhibitor with IC50 of 44 nM, which is 55/125/210/227/ >227 times higher than the selectivity of CDK2/1/4/6/7 respectively. |
target | TargetValue CDK9 (cell-free assay) 44 nM CDK2 (cell-free assay) 2.441 μM |
Target | Value |
CDK9 (Cell-free assay) | 44 nM |
CDK2 (Cell-free assay) | 2.441 μM |
in vitro study | LDC000067 reduce Ser2-P in mESCs, induce p53 activation, and lead to apoptosis. In addition, LDC067 also dose-dependently inhibits RNA de novo synthesis of P-TEFb-dependent cellular genes. |